LFCR News & Events

Lifecore and Indomo announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support the continued development of its corticosteroid drug candidate, DT-001. Indomo is developing DT-001 to be combined with its investigational intradermal self-injection device, the ClearPen, as a treatment for inflammatory acne lesions. This represents the second agreement signed by the companies, with Lifecore having previously been selected to provide formulation and process optimization activities in support of the DT-001 program. Under the terms of the latest agreement, Lifecore will be responsible for producing and supplying engineering and clinical batches of DT-001 to Indomo for planned studies designed to prepare the product for anticipated advancement into Phase 2 clinical trials in 2026.

Lifecore Biomedical announced that it has signed a CDMO master services agreement with a new large global pharmaceutical customer. Under the terms of the agreement, Lifecore will conduct development services and tech transfer for an injectable pharmaceutical product with the intent to transfer commercial supply from facilities overseas to Lifecore's facilities. Once commercial transfer activities are complete and all regulatory requirements are satisfied, Lifecore expects to become the commercial supplier of choice for the product. This is the second agreement that Lifecore has signed in the past three months with a multinational pharmaceutical company. Based on the current commercial revenues for this latest program, the new partner has the potential to become one of Lifecore's top five commercial customers.